peptide analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Historically, men's pain has been treated as abnormal and requiring medical intervention, while women's pain, especially related to menstruation and childbirth, was considered normal and often left untreated. The perception of menstruation-related pain as natural—sometimes reinforced by religious narratives—contributed to this neglect. Pain relief in childbirth gradually advanced, with chemical anesthesia introduced in the 19th century, and techniques such as pain-free childbirth in 1950s France. Epidural anesthesia became common from the 1980s onward. Menstrual pain and conditions like endometriosis (affecting around 10% of women) have only been widely recognized by the medical profession since the late 2010s. Endometriosis was officially recognized as a medical condition in France in 1990. A national awareness plan was launched in 2019, and the disease was classified as a long-term illness in 2022. Some studies suggest that women may delay seeking care, often prioritizing family responsibilities and underestimating their symptoms.
In an interview to Italian newspaper Corriere della Sera on 20 June, Lula asserted that Italy is a priority for Brazil, especially because Brazil has "30 million Brazilians of Italian descent and great relations with Italian trade unions, intellectuals and companies". On 20 June, Lula met with left-wing sociologist and professor emeritus at the Sapienza University of Rome Domenico De Masi during his visit to Rome. On 21 June, Lula met with General Secretary of the Democratic Party (PD), Elly Schlein, and former Prime Minister Massimo D'Alema, with whom he reportedly had talks about "democracy, world peace, climate change, inequality and challenges common to several countries". Brazilian government officials also said that Lula and Schlein had a talk about "gender violence and sexism in politics". Lula also met and dined with Italian president Sergio Mattarella at the Quirinal Palace to reportedly discuss about the relations between Brazil and Italy, as well as the Mercosur-European Union deal. Upon returning from his visit to the Vatican, he also had a meeting with Italian Prime Minister Giorgia Meloni at the Chigi Palace. During an interview to the press after the meeting, he praised Meloni, saying that "ideological differences wouldn't end diplomacy" between the two countries. Lula also had a meeting and private dinner with Rome mayor Roberto Gualtieri.
This is a list of investigational substance-related disorder drugs, or drugs that are currently under development for clinical use for the treatment of substance-related disorders but are not yet approved. Substance-related disorders include substance use disorders like alcoholism (alcohol use disorder), amphetamine use disorder, cocaine use disorder, nicotine use disorder, and opioid use disorder, among others. In addition, they include substance withdrawal syndromes like alcohol withdrawal and opioid withdrawal as well as substance overdoses like opioid overdose. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". This list was last comprehensively updated in January 2026. It is likely to become outdated with time.
The expansion of Toronto in the east, in the 19th century, led to the development of housing stock along the Kingston Road and Danforth Road corridors in Scarborough. This led to the creation of a transit line. In 1893, the Toronto and Scarboro' Electric Railway, Light and Power Company built a single-track radial line along Kingston Road to Blantyre. Over the next 13 years this was extended to West Hill. In 1904, the line became the Scarboro Division of the Toronto and York Radial Railway. Service continued along this line until 1936 when it was replaced by bus service.
=== After the Islamabad Memorandum === Following the resumption of hostilities on July 8, ending the Islamabad Memorandum, initial punitive strikes against Iran had gradually morphed into an attempt to "break Iran’s grip on the strait".
Sources: en.wikipedia.org
==== Maintenance of the secret budget ==== During the electoral campaign, Lula repeatedly criticized the practice of the National Congress of allocating an increasingly relevant portion of the Union Budget to rapporteur's amendments, which critics called the secret budget, due to the lack of transparency regarding the amounts of each transfer and the names of the parliamentarians involved, and which was used by the Bolsonaro government to gather political support in parliament. After the election, Lula used his influence with the Supreme Federal Court to obtain a decision declaring the secret budget unconstitutional, by a narrow majority. At the time, the president of the Chamber of Deputies, Arthur Lira, alleged that he had seen Lula's interference in the vote of Ricardo Lewandowski, who after his retirement was invited to join the government as Minister of Justice. Despite the declaration of unconstitutionality, the National Congress continued in 2023 and 2024 with the same level of control over the budget, without transparency, replacing rapporteur's amendments with committee amendments and Pix amendments. In 2024, the non-transparent amendments will pay almost 25 billion reais.
== Synopsis == Luo Zijun lives a peaceful life as a full-time housewife, yet is unaware of the cracks in her marriage. One day, her husband Chen Junsheng files for divorce, and she is shocked. After divorce, Luo Zijun heads back into the workforce with the help of her dear friend Tang Jing and He Han, both being white-collar workers and elites.
=== Radioisotope thermoelectric generators (RTGs) === The radioactive decay of 90Sr generates a significant amount of heat, 0.920 W/g in the form of pure strontium metal or 0.445 W/g as strontium titanate and is cheaper than the alternative 238Pu. It is used as a heat source in many Russian/Soviet radioisotope thermoelectric generators, usually in the form of strontium titanate. It was also used in the US "Sentinel" series of RTGs. Startup company Zeno Power is developing RTGs that use strontium-90 from the DOD, and is aiming to ship product by 2026.
In addition to producing feminization, estrogens have antigonadotropic effects, suppressing testosterone and other gonadal sex hormones. Levels of estradiol of 200 pg/mL and above suppress testosterone levels by about 90%, while estradiol levels of 500 pg/mL and above suppress testosterone levels by about 95%, or to an equivalent extent as surgical castration and GnRH modulators. Lower levels of estradiol can also considerably but incompletely suppress testosterone production. When testosterone levels are insufficiently suppressed by estradiol alone, antiandrogens can be used to suppress or block the effects of residual testosterone. Oral estradiol often has difficulty adequately suppressing testosterone levels, due to the relatively low estradiol levels achieved with it.
== Mechanism of action == When a tumor stimulates the growth of new vessels, it is said to have undergone an 'angiogenic switch'. The principal stimulus for this angiogenic switch appears to be oxygen deprivation, although other stimuli such as inflammation, oncogenic mutations and mechanical stress may also play a role. The angiogenic switch leads to tumor expression of pro-angiogenic factors and increased tumor vascularization. Specifically, tumor cells release various pro-angiogenic paracrine factors (including angiogenin, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor-β (TGF-β). These stimulate endothelial cell proliferation, migration and invasion resulting in new vascular structures sprouting from nearby blood vessels. Cell adhesion molecules, such as integrins, are critical to the attachment and migration of endothelial cells to the extracellular matrix.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.